Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2025-01-29 Regulatory Filings
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Abivax Publishes 2025 Financial Calendar
Regulatory Filings Classification · 1% confidence The document is titled "Abivax Publishes 2025 Financial Calendar" and explicitly lists the dates for future corporate events, including the release of the 2024 Annual Report (mentioning Form 20-F), Q1 Results, AGM, Half-Year Report, and Q3 Results. Since the document's primary purpose is to announce the schedule of future financial reporting and corporate events, it fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports. It is not the report itself (like 10-K or IR), nor is it a transcript (CT) or a specific financial result release (ER).
2025-01-29 English
Abivax publie son calendrier financier 2025
Report Publication Announcement Classification · 1% confidence The document is a press release from Abivax announcing its 'calendrier financier 2025' (2025 financial calendar). It lists future dates for the publication of annual reports, quarterly results, and the annual general meeting. It does not contain the actual financial reports themselves, but rather serves as an announcement regarding the timing of future report releases. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement.
2025-01-28 French
Abivax Publishes 2025 Financial Calendar
Regulatory Filings Classification · 1% confidence The document is titled "Abivax Publishes 2025 Financial Calendar" and explicitly lists the dates for future corporate events, including the release of the 2024 Annual Report (mentioning Form 20-F), Q1 Results, AGM, Half-Year Report, and Q3 Results. Since the document's primary purpose is to announce the schedule of future financial reporting and corporate events, it fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports. It is not the report itself (like 10-K or IR), nor is it a transcript (CT) or a specific financial result release (ER).
2025-01-28 English
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.12.24.
Regulatory Filings Classification · 1% confidence The document is a formal notification from ABIVAX regarding the total number of shares and voting rights as of December 31, 2024, in accordance with Article L. 233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation. This type of disclosure is a standard regulatory requirement for listed companies in France to inform the market about capital structure changes and voting rights, which falls under the 'Regulatory Filings' category as it does not represent a specific corporate action like a dividend, share buyback, or management change.
2025-01-27 French
ABIVAX: Nombre dactions composant le capital social et nombre total de droits de vote au 31.12.24.
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a regulatory announcement from ABIVAX dated January 27, 2025, detailing the 'Nombre d’actions composant le capital social et nombre total de droits de vote au 31.12.24' (Number of shares comprising the share capital and total number of voting rights as of 12/31/24). This specific disclosure, mandated by French commercial code (article L. 233-8 II) and AMF regulations, relates to the company's capital structure and voting power as of a specific date. This type of filing, which reports on the total number of shares and voting rights, is most closely aligned with announcements concerning capital structure changes or mandatory regulatory disclosures about share counts. While it touches upon capital, it is a periodic disclosure of the existing structure rather than a fundraising event (CAP) or a share repurchase (POS). It is a specific regulatory update on share count. Given the options, this information is a fundamental aspect of corporate structure reporting. Since there isn't a specific code for 'Share Capital Disclosure', and it is a mandatory regulatory filing concerning the share base, it fits best under 'Regulatory Filings' (RNS) as a general regulatory update, or potentially 'Share Issue/Capital Change' (SHA) if interpreted broadly as a capital structure report. However, since it is a routine, periodic disclosure of the *current* count, and not an announcement of a *change* (like an issuance or buyback), RNS is the most appropriate fallback for a specific, non-standard report type. The document itself is short and is an 'Information réglementaire transmise par EQS Group', suggesting it is a notification rather than a comprehensive report.
2025-01-27 French
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohns and Colitis Organization 20th Annual Congress
Regulatory Filings Classification · 1% confidence The document is a press release dated January 23, 2025, announcing that Abivax will present seven scientific abstracts related to its drug candidate, obefazimod, at the 2025 European Crohn’s and Colitis Organization (ECCO) Annual Congress. This is an announcement about upcoming scientific data presentation, not the release of a full financial report (like 10-K or IR), a management change (MANG), or a formal regulatory filing detailing insider trades (DIRS) or capital structure changes (CAP/SHA). Since it is an announcement detailing scientific/clinical data presentation, it fits best under the general category of Investor Information or Regulatory Filings. Given the options, this type of announcement, which is essentially a corporate news release detailing scientific progress and upcoming presentations, is often categorized as a general Regulatory Filing (RNS) or sometimes an Investor Presentation (IP) if it were the presentation itself. However, since it is an announcement *about* presentations at a congress, and not a formal financial report, RNS serves as the most appropriate general regulatory/corporate news category when specific scientific/clinical update codes are absent. It is not a Call Transcript (CT) or an Earnings Release (ER). It is a corporate news announcement.
2025-01-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.